Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHaifaa AbdulhaqJRJames Relf

Discussion

Loading...

Member takes

Overview

Predictive model identifies low-risk patients for grade ≥2 CRS in relapsed DLBCL after glofitamab treatment, suggesting safer management.

Key Points

  • Assess the performance of the CRS-RS.5p model in patients with relapsed diffuse large B-cell lymphoma treated with glofitamab.
  • Applied the CRS-RS.5p model based on 5 baseline factors.
  • Conducted multivariate logistic regression analysis for risk assessment.
  • Classified patients as low-risk or high-risk for CRS after glofitamab administration.
  • CRS occurred in 35.5% of patients receiving glofitamab, predominantly Grade 1.
  • CRS-RS.5p accurately predicted Grade ≥2 CRS in 67% of cases overall and 86% in third-line plus settings.
  • Negative predictive values for low-risk classification were 94% in the overall population and 97% in the 3L+ setting.

Cite This Study

Abdulhaq et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d982https://doi.org/10.1182/blood-2025-2559
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience2025
  2. 2Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience2025
  5. 5Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025 · 3 citations